Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.

Autor: Maesaka, Kazuki1 (AUTHOR), Sakamori, Ryotaro1 (AUTHOR), Yamada, Ryoko1 (AUTHOR), Tahata, Yuki1 (AUTHOR), Imai, Yasuharu2 (AUTHOR), Ohkawa, Kazuyoshi3 (AUTHOR), Miyazaki, Masanori4 (AUTHOR), Mita, Eiji5 (AUTHOR), Ito, Toshifumi6 (AUTHOR), Hagiwara, Hideki7 (AUTHOR), Yakushijin, Takayuki8 (AUTHOR), Kodama, Takahiro1 (AUTHOR), Hikita, Hayato1 (AUTHOR), Tatsumi, Tomohide1 (AUTHOR), Takehara, Tetsuo1 (AUTHOR) takehara@gh.med.osaka-u.ac.jp
Zdroj: Hepatology Research. Mar2022, Vol. 52 Issue 3, p298-307. 10p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje